Iluvien gains traction in Europe

Alimera Sciences today announced that Norway is the eighth European country to grant national approval for Iluvien for diabetic macular edema. In addition, Portugal approved reimbursement for the fluocinolone acetonide implant.

Iluvien is also approved in Austria, the United Kingdom, Portugal, France, Italy, Germany, and Spain. The iimplant is currently under review by the U.S. FDA and is pending approval in an additional nine European countries, including Belgium, the Czech Republic, Denmark, Finland, Ireland, Luxembourg, the Netherlands, Poland and Sweden.

 “With marketing approval in Norway and reimbursement approval in Portugal, Iluvien is gaining traction across Europe,” said Dan Myers, Alimera’s president and chief executive officer. “We are committed to providing widespread patient access to this effective, long-term treatment.”